Scarica l'app Stockscreener
2.42
1.22%
-0.03
Dopo l'orario di chiusura:
2.42
Precedente Chiudi:
$2.45
Aprire:
$2.43
Volume 24 ore:
246.31K
Relative Volume:
0.57
Capitalizzazione di mercato:
$317.50M
Reddito:
-
Utile/perdita netta:
$-151.16M
Rapporto P/E:
-0.8148
EPS:
-2.97
Flusso di cassa netto:
$-130.08M
1 W Prestazione:
+9.50%
1M Prestazione:
+72.86%
6M Prestazione:
+106.84%
1 anno Prestazione:
+116.07%
Intervallo 1D:
$2.36
$2.53
Intervallo di 1 settimana:
$2.12
$2.66
Portata 52W:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Nome
Alx Oncology Holdings Inc
Settore
Industria
Telefono
650-466-7125
Indirizzo
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.42 | 321.43M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.67 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Jefferies | Buy |
| 2025-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-08 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-06 | Iniziato | UBS | Buy |
| 2021-02-10 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Iniziato | Credit Suisse | Outperform |
| 2020-08-11 | Iniziato | Jefferies | Buy |
| 2020-08-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
EV Market: Is ALX Oncology Holdings Inc a stock for growth or value investorsEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
ALX Oncology (ALXO) Expected to Announce Earnings on Friday - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Is ALX Oncology Holdings Inc. stock dividend yield sustainable2025 Historical Comparison & Fast Entry and Exit Trade Plans - mfd.ru
ALX Oncology Pursues Multiple Near-Term Catalysts For Two Novel Cancer Treatments - RTTNews
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 - Investing News Network
Analyst Upgrade: Does ALX Oncology Holdings Inc stock have upside surprise potential2025 Market Sentiment & Growth Oriented Trade Recommendations - baoquankhu1.vn
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 - Bitget
Why ALX Oncology Holdings Inc. stock could outperform in 2025Trade Signal Summary & Verified Momentum Stock Alerts - mfd.ru
Growth Recap: Is Expeditors International of Washington Inc stock trending bullishJuly 2025 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
Does ALX Oncology Holdings Inc. have strong EBITDA marginsWeekly Trade Review & Accurate Intraday Trading Signals - mfd.ru
Will ALX Oncology Holdings Inc. outperform tech stocksGDP Growth & Expert Verified Stock Movement Alerts - mfd.ru
Can ALX Oncology Holdings Inc. reach all time highs this yearWeekly Profit Summary & Fast Moving Stock Trade Plans - mfd.ru
Will ALX Oncology Holdings Inc. stock pay special dividends2025 EndofYear Setup & Safe Investment Capital Preservation Plans - mfd.ru
Will ALX Oncology Holdings Inc. stock benefit from upcoming earnings reports2025 Risk Factors & Weekly High Momentum Picks - mfd.ru
Will ALX Oncology Holdings Inc. stock hit new highs in YEARQuarterly Trade Review & Breakout Confirmation Alerts - mfd.ru
Meme Stocks: Can ALX Oncology Holdings Inc reach all time highs this yearJuly 2025 Spike Watch & Reliable Breakout Forecasts - baoquankhu1.vn
Is ALX Oncology Holdings Inc. a stock for growth or value investorsPortfolio Performance Summary & Stepwise Trade Signal Implementation - mfd.ru
ALX Oncology announces pricing of underwritten offering; shares up nearly 15% - MSN
3 Promising Penny Stocks With Market Caps Over $100M - Yahoo Finance
Is ALX Oncology Holdings Inc. stock forming a triangle patternJuly 2025 Price Swings & Weekly Stock Breakout Alerts - mfd.ru
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Institutional Investor Builds Significant Stake in ALX Oncology - AD HOC NEWS
ALXO: Analyst Raises Price Target to $4.00, Maintains Overweight Rating | ALXO Stock News - GuruFocus
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ALX Oncology (ALXO) Rises on Significant Share Purchase by venBi - GuruFocus
ALX Oncology (NASDAQ:ALXO) Director Corey Goodman Acquires 3,184,713 Shares - MarketBeat
Wilson Sonsini Advises ALX Oncology on Public Offering - Wilson Sonsini
CD47 Protein May Predict Evorpacept Success in Metastatic Breast Cancer - Cure Today
ALX Oncology Prices $150 Mln Offering Of Shares And Pre-funded Warrants - Nasdaq
ALX Oncology prices $150 million stock offering at $1.57 per share - Investing.com Nigeria
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera in Advanced HER2-Positive Breast Cancer - Investing News Network
ALX Oncology reports CD47 biomarker findings in breast cancer trial By Investing.com - Investing.com Nigeria
ALXO Unveils Promising Data from Evorpacept Trial in Breast Canc - GuruFocus
ALX Oncology announces major underwritten public equity offering - TipRanks
ALX Oncology Announces Pricing of Underwritten Offering - The Manila Times
ALX Oncology reports CD47 biomarker findings in breast cancer trial - Investing.com
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - The Manila Times
ALX Oncology Holdings Inc Announces New Clinical Trial Data - TradingView
What is ALX Oncology Holdings Inc.’s book value per shareTrade Exit Report & Daily Chart Pattern Signals - mfd.ru
IPO Launch: Is ALX Oncology Holdings Inc affected by consumer sentimentPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
VIX Spike: Is ALX Oncology Holdings Inc in accumulation or distribution phase2025 Technical Patterns & Verified Swing Trading Watchlist - baoquankhu1.vn
Investment Report: Will ALX Oncology Holdings Inc stock hit new highs in YEARIPO Watch & AI Forecasted Entry/Exit Points - baoquankhu1.vn
ALX Oncology increases shares reserved for inducement equity plan By Investing.com - Investing.com Nigeria
ALX Oncology increases shares reserved for inducement equity plan - Investing.com
ALX Oncology Expands Inducement Equity Plan for Hiring - TipRanks
Aug Volume: How does QuantumScape Corporation correlate with NasdaqEarnings Miss & Weekly High Momentum Picks - baoquankhu1.vn
Alx Oncology Holdings Inc Azioni (ALXO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alx Oncology Holdings Inc Azioni (ALXO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GOODMAN COREY S | Director |
Feb 02 '26 |
Buy |
1.57 |
3,184,713 |
4,999,999 |
8,453,038 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jan 06 '26 |
Sale |
1.11 |
3,925 |
4,357 |
88,273 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
2.25%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):